ストックスクリーナーアプリを入手
2.84
9.78%
-0.33
Beyondspring Inc (BYSI) 最新ニュース
BeyondSpring (NASDAQ:BYSI) Shares Up 30%Should You Buy? - MarketBeat
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
BeyondSpring reports promising phase 2 NSCLC study results By Investing.com - Investing.com South Africa
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study - GuruFocus
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - marketscreener.com
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com Australia
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Canc - GuruFocus
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Cancer Study | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Promising Interim Phase 2 Data for Plinabulin in Metastatic NSCLC Showing 6.8 Months Median PFS and 78% Overall Survival Rate - Nasdaq
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 - GlobeNewswire
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - TradingView
New Clinical Data: BeyondSpring's Triple Therapy Doubles Survival in Drug-Resistant Lung Cancer Patients - Stock Titan
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting | BYSI Stock News - GuruFocus
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting - GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Neutropenia Drugs Market Revenue to Surpass USD 24.2 Billion by 2033 with 4.7% CAGR - openPR.com
Should You Buy, Hold or Sell OKTA Stock Before Q1 Earnings Release? - The Globe and Mail
BeyondSpring Reports Q1 2025 Financials and Clinical Progress - TipRanks
BeyondSpring (NASDAQ:BYSI) Posts Earnings Results - MarketBeat
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Yahoo Finance
Can Saudi AI Deals Boost AMD Over NVIDIA, and Is It a Buy? - The Globe and Mail
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.08 - StreetInsider
BeyondSpring Reports First?Quarter 2025 Financial Results and Provides Corporate Update | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress - Nasdaq
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring (NASDAQ:BYSI) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
BeyondSpring stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.34 amid market challenges - Investing.com India
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
0.66%
1.05%
大文字化:
|
ボリューム (24 時間):